Study did not meet primary endpoint nor notable secondary endpoints – no benefit observed in either treatment arm versus shamAdditional analyses to be conducted and presented at a future medical congressSepofarsen continues to be generally well tolerated
… ProQR spins out all Dystrophic Epidermolysis Bullosa … and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … in a dedicated effort,” said Daniel A. de Boer, CEO at ProQR. “With this transaction we’ve now fully focused our …